EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proposal of metagenomic-origin LRA-5 as a precursor of active β-lactamases through Tyr69Gln and Val166Glu amino acid substitutions: a functional and structural analysis

Gabriela D'Amico González, María Margarita Rodríguez, Pedro Penzotti, Florencia Brunetti, Barbara Ghiglione, Luke A Moe iD, Daniela Centrón, Gabriel Gutkind iD, Lin Gao, Shozeb Haider iD, Rachel A Powers iD, Sebastián Klinke iD und 1 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00675-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Gabriela D'Amico González und 12 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Buenos …. Hauptthemen laut MEDLINE: beta-Lactamases. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Wild-type LRA-5, recovered from Alaskan soil samples, shares no more than 33% amino acid sequence identity with enzymes from pathogens like PER β-lactamases. Recombinant E. coli expressing wild-type LRA-5 and its engineered variants LRA-5 Y69Q and LRA-5 V166E showed MIC values equivalent to control strains. However, LRA-5 Y69Q/V166E displayed MICs above the resistant breakpoint for some β-lactams. Kinetic parameters correlated with the MICs, showing that the catalytic efficiency of LRA-5 Y69Q/V166E was comparable to those from class A β-lactamases, such as CTX-M-15, PER-2, and KPC-2. LRA-5 Y69Q/V166E exhibited k cat / K m values up to 11,000-fold higher compared to wild-type LRA-5, which is associated with the presence of Glu166. The X-ray crystallographic structure of wild-type LRA-5 (1.80 Å; PDB 8EO5) shows that the lack of both Glu166 and a deacylation water molecule contributes to a biologically insignificant activity. Interactions observed between LRA-5 and ceftazidime (2.35 Å; PDB 8EO6) show structural conservation with other β-lactamases. In contrast, the crystallographic structure of LRA-5 Y69Q/V166E (2.15 Å; PDB 8EO7) bears a deacylation water molecule that is associated with the increase in catalytic activity compared to the wild-type variant. Circular dichroism results confirm that amino acid substitutions in LRA-5 do not affect the overall content of the secondary/tertiary structures. Evidence suggests that alternative evolutionary paths could have occurred for β-lactamases like LRA-5, produced by environmental microorganisms: (i) proteins having similar structural features than active β-lactamases may accumulate a small number of mutations (e.g., Y69Q/V166E) to yield active enzymes and (ii) the β-lactamase fold may have lost key residues in the absence of antibiotics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamasesAmino Acid SubstitutionEscherichia coliMicrobial Sensitivity TestsAnti-Bacterial AgentsKineticsCrystallography, X-RayAmino Acid SequenceSoil Microbiologybeta-Lactams

Stichwörter der Autor:innen

Alaskan soil metagenomeX-ray crystallographyceftazidimeβ-lactamase evolutionβ-lactamase precursor

Substanzen

beta-LactamasesAnti-Bacterial Agentsbeta-Lactams

Autor:innen und Institutionen

  • Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Buenos Aires, Argentina.
  • Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
  • University of Kentucky, Plant and Soil Sciences, Lexington, Kentucky, USA.
  • Facultad de Medicina, Instituto de Investigaciones en Microbiología y Parasitología Médica (IMPaM), Universidad de Buenos Aires, Buenos Aires, Argentina.
  • UCL School of Pharmacy, London, United Kingdom.
  • UCL Centre for Advanced Research Computing, London, United Kingdom.

ORCID-Profile: Luke A Moe, Gabriel Gutkind, Shozeb Haider, Rachel A Powers, Sebastián Klinke, Pablo Power

Förderung

  • NIAID NIH HHS
  • Universidad de Buenos Aires
  • Consejo Nacional de Investigaciones Científicas y Técnicas
  • NIH HHS
  • Agencia Nacional de Promoción Científica y Tecnológica
  • National Institutes of Health

Zitieren

APA

D'Amico González, G., Rodríguez, M. M., Penzotti, P., Brunetti, F., Ghiglione, B., Moe, L. A., Centrón, D., Gutkind, G., Gao, L., Haider, S., Powers, R. A., Klinke, S., & Power, P. (2026). Proposal of metagenomic-origin LRA-5 as a precursor of active β-lactamases through Tyr69Gln and Val166Glu amino acid substitutions: a functional and structural analysis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00675-25

Vancouver

D'Amico González G, Rodríguez MM, Penzotti P, Brunetti F, Ghiglione B, Moe LA, et al. Proposal of metagenomic-origin LRA-5 as a precursor of active β-lactamases through Tyr69Gln and Val166Glu amino acid substitutions: a functional and structural analysis. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00675-25

BibTeX
@article{DAmicoGonzlez2026,
  author = {D'Amico González, Gabriela and Rodríguez, María Margarita and Penzotti, Pedro and Brunetti, Florencia and Ghiglione, Barbara and Moe, Luke A and Centrón, Daniela and Gutkind, Gabriel and Gao, Lin and Haider, Shozeb and Powers, Rachel A and Klinke, Sebastián and Power, Pablo},
  title = {Proposal of metagenomic-origin LRA-5 as a precursor of active β-lactamases through Tyr69Gln and Val166Glu amino acid substitutions: a functional and structural analysis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00675-25}
}
Kostenlos starten →